Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Dako Launches Two Ready-to-Use Antibodies for Cancer Diagnosis

Published: Wednesday, May 07, 2014
Last Updated: Tuesday, May 06, 2014
Bookmark and Share
Company announces addition of Anti-CK 8/18 and Anti-TdT antibodies for routine diagnostic use.

Dako has announced the addition of two new antibodies, Anti-CK 8/18 and Anti-TdT, to the Dako portfolio of high-quality reagents, instruments and software.

Anti-CK 8/18 is the first rabbit monoclonal antibody cocktail for cytokeratin 8/18 (CK 8/18) available from a major pathology provider. It is used by pathologists to stain CK 8/18 in tissue samples and thereby help classify tumors of unknown origin. Keratins are one of the most potent epithelial differentiation and tumor markers in cancer diagnostics.

Anti-TdT, also a rabbit monoclonal antibody, is used to help classify lymphoma and leukemia by staining terminal deoxynucleotidyl transferase (TdT) in tissue samples. In immunohistochemistry, antibodies to TdT can be used to demonstrate the presence of pre-T and pre-B cells and multipotent hematopoietic stem cells that possess the antigen.

Both Anti-CK 8/18 and Anti-TdT provide excellent specificity and sensitivity and have been reviewed and accepted by key pathology experts. Both antibodies provide optimal staining results enabled by the FLEX Ready-to-Use Dako solutions.

FLEX Ready-to-Use is a plug-and-play solution consisting of pre-diluted antibodies, a visualization system, and optimized validated protocols developed in collaboration with leading pathology experts.

The protocols are developed to take into account pre-analytical variations and different ways of processing and handling tissue samples, ensuring optimal staining results for pathology labs.

"With the FLEX RTU solution, it takes less time for a lab to validate new antibodies for routine diagnostic use," said Hans Christian Pedersen, global product manager, Dako IHC reagents. "FLEX Ready-to-Use antibodies are helping labs get high-quality results from day one."

"We are pleased to add these two high-quality antibodies to our comprehensive offering to pathologists around the world," said Britt Meelby Jensen, vice president of Marketing and Pathology Sales in Agilent's Diagnostics and Genomics business. "One of our goals is to constantly establish new quality benchmarks within IHC reagents."

Both products are available from Dako now as 1.0 mL concentrates and 12 mL (60 tests) FLEX RTUs for Autostainer Link 48.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Agilent Technologies, University of Rouen and A*STAR’s Bioprocessing Technology Institute Collaborate
Organisations will work together to further innovation in biopharmaceuticals and glycomics.
Thursday, May 23, 2013
Dako to Offer New Antibody in U.S. to Diagnose Breast Cancer
Dako receives clearance to sell FLEX Monoclonal Rabbit Anti-Human Estrogen Receptor a, Clone EP1 in US.
Monday, April 08, 2013
Scientific News
Gut Bacteria Older than Human Species
Some bacteria have lived in the human gut since before we were human, suggesting evolution could have a larger role inhuman bacterial makeup.
Evidence of Mosquito Transmitting Zika
A direct link between the Yellow fever mosquito and Zika transmission has been found following investigation into selective mosquito control.
Antibody-Based Drug for Multiple Sclerosis
New antibody-based drug paves the way for new strategies for controlling and treating multiple sclerosis.
Three-Drug Combinations Counter Antibiotic Resistance
Research shows that combinations of three different antibiotics can treat resistant bacteria, even if they are ineffective independently.
Mapping Zika’s Routes to Developing Fetus
UC researchers show how Zika virus travels from a pregnant woman to her fetus, and also identified a drug that could stop it.
Treating HIV with Cancer-Fighting Gene Shows Promise
A type of gene immunotherapy that has shown promising results against cancer could also be used against HIV.
Protein Teams Activate T-Cells
Caltech researchers have discovered T-cell genetic switching is controlled by four proteins acting in a multi-tiered fashion.
'Antigen-Presenting Cell' Defends Against Cancer
Through advanced imaging, researchers have identified cells that encourages increases in immune system cancer defences.
Zika Epidemic Likely to End Within Three Years
A team of scientists has predicted that the current Zika epidemic is likely to end within three years because there will be too few people left to infect.
Go-Between Immune Cell is Key to Priming the Body’s Fight Against Cancer
‘Antigen-presenting cell’ activates T cells by alerting them to the presence of tumors.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!